This article is more than 5 years old. Information may no longer be current.

AHA sessions to feature cutting-edge science, anticipated trials

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The American Heart Association Scientific Sessions, taking place in New Orleans from Nov. 12 to Nov. 16, will feature more than 15 late-breaking clinical trials, as well as numerous additional presentations.

“We’re very excited to have these trials on the program," said Frank Sellke, MD, chief of cardiothoracic surgery at Brown University and chairman of Committee on Scientific Sessions Program for the AHA, said during a press conference. “We had a near-record number of submissions.”

Late-breaking trials

According to Sellke, two of the most anticipated highlights from AHA 2016 are the ART trial, which will present the 5-year results of the largest randomized trial of bilateral mammary artery CABG compared with standard single mammary artery grafting plus vein grafts and the FUTURE trial, a randomized, controlled, multicenter study comparing fractional flow reserve-guided therapeutic management with conventional therapeutic management in patients with multivessel CAD.

He said other highlights from the meeting include:

• Results of the GERMANY study comparing outcomes of intermediate-risk patients receiving TAVR or conventional surgical AVR from the prospective, multicenter German Aortic Valve Registry (GARY)

• ORION 1, which will provide information on safety and efficacy of using RNA interference quarterly or biannually to target intracellular PCSK9 production as a means to lower LDL in a large patient cohort

• The EUCLID trial, designed to test if long-term monotherapy treatment with ticagrelor (Brilinta, AstraZeneca) would be superior to clopidogrel at preventing CV death, MI or ischemic stroke in patients with symptomatic peripheral artery disease

• The PRECISION trial comparing CV outcomes with three commonly used nonsteroidal anti-inflammatory drugs in patients at high CV risk; and

• A substudy of HOPE-3 evaluating whether long-term cholesterol lowering or BP lowering delayed cognitive decline.

Additional Submissions

According to Sellke, the AHA received a near-record number of submissions in 2016, which were all very laudatory.

“In addition to these [late-breaking] trials, we have about another 20 ... [that] could also be game-changers, so when you're at the scientific sessions, be sure to check these out,” he said.

Cardiology Today and healio.com/cardiology will be covering the AHA Scientific Sessions live. Check healio.com/cardiology for news, perspectives and videos from the meeting.